CLINICALLY PROVEN RESULTS IN ADULTS
MARRIKA
Treating her SBS with GATTEX
For adults with SBS, GATTEX may reduce the need for parenteral support (PS)
How effective is GATTEX?
GATTEX was evaluated in 2 trials, STEPS (Study 1) and STEPS-2 (Study 2).
STEPS: In this 6-month study of 86 adults (aged 18 and over) with SBS who needed PS, 43 received GATTEX and 43 received placebo. The study's main goal was to evaluate the ability of GATTEX to reduce patients' weekly PS volume by at least 20% from baseline to both weeks 20 and 24. The study also evaluated the average reduction of weekly PS volume from baseline, the number of people who reduced PS administration by at least 1 day per week, and safety.
STEPS-2: In this 24-month study of 88 adults (aged 18 and over) with SBS who needed PS, 76 had participated in STEPS (Study 1). The study's main goal was to evaluate the average reduction of weekly PS volume since the beginning of the study. The study also looked at the percentage of people who achieved at least a 20% reduction in weekly PS volume, the number of people who reduced their PS administration by at least 3 days per week, the number of people who completely stopped PS, and safety.